Source:http://linkedlifedata.com/resource/pubmed/id/12437653
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2002-11-19
|
pubmed:abstractText |
We hypothesized that patients undergoing major ABO-incompatible non-myeloablative haematopoietic stem cell transplantation (nm-HSCT) might experience prolonged haemolysis after transplant due to the delayed disappearance of host plasma cells producing anti-donor isohaemagglutinins (HAs). To address this question, we analysed data from 107 consecutive patients transplanted with allogeneic peripheral blood stem cells from human leucocyte antigen-matched (related, n = 84; unrelated, n = 23) donors after non-myeloablative conditioning (200 cGy total body irradiation +/- fludarabine). In total, 23 out of the 107 patients received major or major/minor ABO-incompatible transplants. Red blood cell (RBC) transfusion requirements during the first 120 d post transplant were higher in major ABO-mismatched than in ABO-matched recipients (0.12 vs 0.03 median units RBC concentrate/d, P = 0.04). Two patients developed transient pure red cell aplasia, which had resolved spontaneously by 9 months after transplant. Major ABO incompatibility did not influence rates of engraftment. Patients with sustained engraftment experienced gradual declines of anti-donor HAs, and the estimated median time to reaching IgM and IgG titres of < 1:1 was at least 133 d in evaluable patients, approximately twice longer than reported after myeloablative conditioning. There was a strong correlation between degrees of donor chimaerism in erythroid burst-forming units, granulocyte macrophage colony-forming units and granulocytes, indicating that donor erythroid engraftment, defined by early erythroid progenitors, was as prompt as myeloid engraftment. In conclusion, our data suggest that major ABO-incompatibility is not a barrier to successful non-myeloablative HSCT.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/673166,
http://linkedlifedata.com/resource/pubmed/grant/CA15704,
http://linkedlifedata.com/resource/pubmed/grant/CA18029,
http://linkedlifedata.com/resource/pubmed/grant/CA18221,
http://linkedlifedata.com/resource/pubmed/grant/CA78902,
http://linkedlifedata.com/resource/pubmed/grant/HL36444,
http://linkedlifedata.com/resource/pubmed/grant/K23 CA92058
|
pubmed:language |
eng
|
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:author |
pubmed-author:BakerJenniferJ,
pubmed-author:ChaunceyThomasT,
pubmed-author:GooleyTheodoreT,
pubmed-author:LittleMarie-TereseMT,
pubmed-author:Maciej ZauchaJJ,
pubmed-author:MaloneyDavid GDG,
pubmed-author:MarisMichaelM,
pubmed-author:MielcarekMarcoM,
pubmed-author:SandmaierBrenda MBM,
pubmed-author:StorbRainerR,
pubmed-author:TakatuAlessandraA,
pubmed-author:Torok-StorbBeverlyB
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
740-50
|
pubmed:dateRevised |
2008-11-21
|
pubmed:articleTitle |
Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
|
pubmed:affiliation |
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
|